- Home
- BLFS vs PHAT Comparison
BLFS vs PHAT Comparison
Compare BLFS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | PHAT |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 894.0M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BLFS | PHAT |
|---|---|---|
| Price | $21.91 | $12.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $32.00 | $19.83 |
| AVG Volume (30 Days) | 326.0K | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | 42.72 |
| EPS | ★ 0.02 | N/A |
| Revenue | $96,214,000.00 | ★ $175,110,000.00 |
| Revenue This Year | $19.73 | $93.04 |
| Revenue Next Year | $17.82 | $58.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.97 | ★ 216.93 |
| 52 Week Low | $17.86 | $3.69 |
| 52 Week High | $29.57 | $18.31 |
Technical Indicators
Market Signals| Indicator | BLFS | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 50.49 |
| Support Level | $21.35 | $10.38 |
| Resistance Level | $26.14 | $12.44 |
| Average True Range (ATR) | 1.03 | 1.03 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 68.35 | 64.24 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.